DexCom, Inc. $DXCM Shares Sold by Marble Harbor Investment Counsel LLC

Marble Harbor Investment Counsel LLC reduced its holdings in DexCom, Inc. (NASDAQ:DXCM) by 24.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 123,572 shares of the medical device company’s stock after selling 39,376 shares during the period. Marble Harbor Investment Counsel LLC’s holdings in DexCom were worth $8,201,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the business. Holocene Advisors LP acquired a new stake in shares of DexCom in the third quarter worth approximately $163,964,000. CIBC Private Wealth Group LLC boosted its stake in shares of DexCom by 374.3% in the third quarter. CIBC Private Wealth Group LLC now owns 2,907,801 shares of the medical device company’s stock worth $195,666,000 after acquiring an additional 2,294,709 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of DexCom by 2.3% in the third quarter. Vanguard Group Inc. now owns 49,456,043 shares of the medical device company’s stock worth $3,327,897,000 after acquiring an additional 1,133,638 shares during the last quarter. Iron Triangle Partners LP acquired a new stake in shares of DexCom in the third quarter worth approximately $57,196,000. Finally, DNB Asset Management AS boosted its stake in shares of DexCom by 271.8% in the third quarter. DNB Asset Management AS now owns 1,098,544 shares of the medical device company’s stock worth $73,921,000 after acquiring an additional 803,086 shares during the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Stock Performance

NASDAQ:DXCM opened at $66.95 on Wednesday. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.64 and a current ratio of 1.95. The stock has a market capitalization of $25.83 billion, a P/E ratio of 28.61, a PEG ratio of 1.12 and a beta of 1.40. The company has a 50 day moving average price of $63.33 and a 200 day moving average price of $65.82. DexCom, Inc. has a fifty-two week low of $54.11 and a fifty-two week high of $89.98.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, April 30th. The medical device company reported $0.56 EPS for the quarter, beating analysts’ consensus estimates of $0.47 by $0.09. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The company had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.17 billion. During the same period last year, the business posted $0.32 EPS. DexCom’s revenue for the quarter was up 15.0% on a year-over-year basis. Equities research analysts forecast that DexCom, Inc. will post 2.56 EPS for the current year.

Insider Transactions at DexCom

In related news, Director Bridgette P. Heller sold 1,012 shares of the firm’s stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $60.01, for a total transaction of $60,730.12. Following the completion of the transaction, the director directly owned 25,007 shares in the company, valued at $1,500,670.07. This trade represents a 3.89% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Jon Brown sold 1,700 shares of the firm’s stock in a transaction dated Wednesday, April 15th. The shares were sold at an average price of $63.04, for a total value of $107,168.00. Following the transaction, the executive vice president owned 111,204 shares of the company’s stock, valued at $7,010,300.16. This trade represents a 1.51% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 6,112 shares of company stock valued at $379,990 over the last 90 days. 0.28% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

DXCM has been the topic of a number of research analyst reports. Raymond James Financial set a $81.00 price target on DexCom in a research note on Friday, May 1st. Sanford C. Bernstein set a $77.00 price target on shares of DexCom in a research report on Friday, May 1st. Weiss Ratings upgraded shares of DexCom from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, March 4th. Wells Fargo & Company lowered their price target on shares of DexCom from $93.00 to $85.00 and set an “overweight” rating on the stock in a research report on Friday, February 13th. Finally, Mizuho set a $75.00 price target on shares of DexCom in a research report on Friday, May 1st. Three research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $82.21.

Key DexCom News

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: DexCom announced Dexcom Flex in Germany, expanding CGM access to a broader Type 2 diabetes population using basal insulin, oral medications, or GLP-1 therapies. Dexcom Announces Dexcom Flex in Germany
• Positive Sentiment: Bank of America lowered its price target to $80 from $100 but kept a buy rating, which still implies upside from current levels. Benzinga report on Bank of America price target
• Neutral Sentiment: Barclays reiterated its sell rating on DexCom, adding a bearish counterpoint that may limit enthusiasm. Barclays sticks to its sell rating
• Negative Sentiment: EVP Michael Jon Brown sold 1,700 shares in a pre-arranged Rule 10b5-1 transaction, which is routine but can still weigh on sentiment when investors are watching insider activity closely. SEC Form 4 filing

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.